{
  "docId": "019dd923-622c-750b-8b97-5cb48bf2a635",
  "docSlug": "b8afd3741673",
  "documentTitle": "Chinook Therapeutics Inc (KDNY)",
  "authorId": "51_Muddy_Waters",
  "authorName": "Carson C. Block",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-05-16 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 26,
  "pageCount": 36,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "sparse",
  "nDataPoints": 6,
  "notes": "The slide highlights inconsistencies between SONAR study reports and FDA filings, suggesting data manipulation to favor the drug's safety profile.",
  "elementsJson": [
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b97-5cb48bf2a635/26",
  "deckHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635#slide-26",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "It is unclear why there should be two entirely different sets of figures for non-fatal strokes, but it is certainly suspicious that the stroke figures as reported in the SONAR paper make atrasentan treatment appear safer than stroke figures reported elsewhere do.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8d1-c483113ad3cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.76,
        "x": 0.118,
        "y": 0.095
      },
      "kind": "paragraph",
      "text": "A detailed critique of how timeline scaling and stroke event reporting in the SONAR study appear to misrepresent the safety profile of atrasentan compared to FDA filings.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be18e1dd-460d-45e8-bf40-84d8521ee313",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.76,
        "x": 0.118,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Footnotes 133, 134, 135 referencing clinicaltrials.gov data.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a92f625b-6952-4373-b682-ab668fee265d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.18,
        "x": 0.118,
        "y": 0.27
      },
      "kind": "title",
      "text": "Manipulated Numbers",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60a4c41f-ff62-4949-bf50-6015c7a10619",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "f326c4d1-f9f8-4126-bac2-40a6c7abde08",
      "evidence": "The slide explicitly identifies and argues for data manipulation and misreporting in clinical trials.",
      "confidence": 0.95
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}